Foghorn Therapeutics Stock Performance
| FHTX Stock | USD 5.71 0.06 1.04% |
On a scale of 0 to 100, Foghorn Therapeutics holds a performance score of 9. The firm shows a Beta (market volatility) of 1.46, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Foghorn Therapeutics will likely underperform. Please check Foghorn Therapeutics' downside variance, and the relationship between the total risk alpha and daily balance of power , to make a quick decision on whether Foghorn Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Foghorn Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Foghorn Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.04) | Five Day Return (7.61) | Year To Date Return 10.02 | Ten Year Return (68.49) | All Time Return (68.49) |
1 | Foghorn Therapeutics Forecast 28.8 percent Revenue Growth Sets High Bar Despite Ongoing Losses | 11/06/2025 |
2 | Foghorn Therapeutics Upgraded at Wall Street Zen - MarketBeat | 11/28/2025 |
3 | Stifel initiates Foghorn Therapeutics stock with Buy rating, 12 target By Investing.com - Investing.com India | 12/03/2025 |
4 | BTIG Research Upgrades Foghorn Therapeutics to Strong-Buy | 12/19/2025 |
5 | Foghorn Therapeutics Inc. Stock Rockets 25 percent As Investors Are Less Pessimistic Than Expected | 12/23/2025 |
6 | Analysts Offer Insights on Healthcare Companies Aldeyra Therapeutics and Foghorn Therapeutics - The Globe and Mail | 01/05/2026 |
7 | Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 - GlobeNewswire | 01/09/2026 |
8 | Acquisition by Flagship Pioneering, Llc of 1117734 shares of Foghorn Therapeutics at 20.13 subject to Rule 16b-3 | 01/13/2026 |
9 | Disposition of 857 shares by Carlos Costa of Foghorn Therapeutics at 10.17 subject to Rule 16b-3 | 01/15/2026 |
10 | Hard-to-Treat Cancers How 2026s Top Clinical Platforms Are Beating Industry Benchmarks - Baystreet.ca | 01/27/2026 |
| Begin Period Cash Flow | 82 M | |
| Total Cashflows From Investing Activities | -29.9 M |
Foghorn Therapeutics Relative Risk vs. Return Landscape
If you would invest 421.00 in Foghorn Therapeutics on November 2, 2025 and sell it today you would earn a total of 150.00 from holding Foghorn Therapeutics or generate 35.63% return on investment over 90 days. Foghorn Therapeutics is currently generating 0.6544% in daily expected returns and assumes 5.679% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Foghorn, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Foghorn Therapeutics Target Price Odds to finish over Current Price
The tendency of Foghorn Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 5.71 | 90 days | 5.71 | about 13.57 |
Based on a normal probability distribution, the odds of Foghorn Therapeutics to move above the current price in 90 days from now is about 13.57 (This Foghorn Therapeutics probability density function shows the probability of Foghorn Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.46 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Foghorn Therapeutics will likely underperform. Additionally Foghorn Therapeutics has an alpha of 0.5958, implying that it can generate a 0.6 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Foghorn Therapeutics Price Density |
| Price |
Predictive Modules for Foghorn Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Foghorn Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Foghorn Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Foghorn Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Foghorn Therapeutics is not an exception. The market had few large corrections towards the Foghorn Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Foghorn Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Foghorn Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.60 | |
β | Beta against Dow Jones | 1.46 | |
σ | Overall volatility | 0.70 | |
Ir | Information ratio | 0.11 |
Foghorn Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Foghorn Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Foghorn Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Foghorn Therapeutics is way too risky over 90 days horizon | |
| Foghorn Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 22.6 M. Net Loss for the year was (86.62 M) with loss before overhead, payroll, taxes, and interest of (59.41 M). | |
| Foghorn Therapeutics currently holds about 373.5 M in cash with (100.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Foghorn Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 70.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Hard-to-Treat Cancers How 2026s Top Clinical Platforms Are Beating Industry Benchmarks - Baystreet.ca |
Foghorn Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Foghorn Stock often depends not only on the future outlook of the current and potential Foghorn Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Foghorn Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 54.9 M | |
| Cash And Short Term Investments | 243.7 M |
Foghorn Therapeutics Fundamentals Growth
Foghorn Stock prices reflect investors' perceptions of the future prospects and financial health of Foghorn Therapeutics, and Foghorn Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Foghorn Stock performance.
| Return On Equity | -4.7 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (2.94) % | ||||
| Operating Margin | (2.27) % | ||||
| Current Valuation | 186.13 M | ||||
| Shares Outstanding | 58.58 M | ||||
| Price To Book | 10.71 X | ||||
| Price To Sales | 13.79 X | ||||
| Revenue | 22.6 M | ||||
| Gross Profit | (59.41 M) | ||||
| EBITDA | (97.17 M) | ||||
| Net Income | (86.62 M) | ||||
| Cash And Equivalents | 373.5 M | ||||
| Cash Per Share | 8.94 X | ||||
| Total Debt | 37.13 M | ||||
| Debt To Equity | 2.19 % | ||||
| Current Ratio | 6.84 X | ||||
| Book Value Per Share | (1.59) X | ||||
| Cash Flow From Operations | (100.41 M) | ||||
| Earnings Per Share | (1.14) X | ||||
| Market Capitalization | 338.02 M | ||||
| Total Asset | 283.98 M | ||||
| Retained Earnings | (558.18 M) | ||||
| Working Capital | 182.61 M | ||||
About Foghorn Therapeutics Performance
Evaluating Foghorn Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Foghorn Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Foghorn Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.29) | |
| Return On Capital Employed | (0.43) | (0.45) | |
| Return On Assets | (0.27) | (0.29) | |
| Return On Equity | 2.19 | 2.30 |
Things to note about Foghorn Therapeutics performance evaluation
Checking the ongoing alerts about Foghorn Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Foghorn Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Foghorn Therapeutics is way too risky over 90 days horizon | |
| Foghorn Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 22.6 M. Net Loss for the year was (86.62 M) with loss before overhead, payroll, taxes, and interest of (59.41 M). | |
| Foghorn Therapeutics currently holds about 373.5 M in cash with (100.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Foghorn Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 70.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Hard-to-Treat Cancers How 2026s Top Clinical Platforms Are Beating Industry Benchmarks - Baystreet.ca |
- Analyzing Foghorn Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Foghorn Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Foghorn Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Foghorn Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Foghorn Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Foghorn Therapeutics' stock. These opinions can provide insight into Foghorn Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.